H. van der Voet

Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.

J. Staffurth, V. Hinder, E. Hall, 2022, The Lancet. Oncology.

Management of muscle‐invasive bladder cancer

J. Cresswell, A. Moon, H. van der Voet, 2015 .

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial

G. Rodrigues, J. Staffurth, T. Tsakiridis, 2019, The Lancet. Oncology.

Toxicity and survival of anal cancer patients treated with intensity‐modulated radiation therapy

A. Ghareeb, M. Jha, H. van der Voet, 2019, Annals of the Royal College of Surgeons of England.

A feasibility study of accelerated fractionation in radiotherapy of carcinoma of the urinary bladder.

H. Bartelink, L. Moonen, S. Horenblas, 1997, International journal of radiation oncology, biology, physics.

PACE-A: An international phase 3 randomised controlled trial (RCT) comparing stereotactic body radiotherapy (SBRT) to surgery for localised prostate cancer (LPCa)—Primary endpoint analysis.

A. Thompson, C. Griffin, E. Hall, 2023, Journal of Clinical Oncology.